Research Progress of 64Cu-Radiopharmaceuticals in Clinical Trial for Tumor Diagnosis

doi:10.7538/tws.2021.34.01.0078

Abstract

Abstract:

Positron computed emission tomography (PET) is an important diagnosis and imaging tool for nuclear medicine with the advantages of high sensitivity, resolution, and safety. It is widely used in the diagnosis of tumors, cardiovascular and cerebrovascular diseases, and so on. ⁶⁴Cu nuclide has become the focus of research in the field of PET molecular probe and theranostic radiopharmaceuticals due to its suitable half-life (12.7 h), unique decay properties （β⁺, 0.653 MeV, 17.4%; β^-, 0.579 MeV, 39%; electron capture） and the ability to form stable complexes with multiple ligands. Currently, more than 30 clinical studies of ⁶⁴Cu-radiopharmaceuticals are on going with focus on neuroendocrine tumors, prostate cancer and hypoxic tumors. The results of these clinical trials of ⁶⁴Cu-radiopharmaceuticals showed that ⁶⁴Cu-radiopharmaceuticals had high resolution, detection rate and good safety. In addition, the long half-life of ⁶⁴Cu nuclide allows ⁶⁴Cu nuclide and ⁶⁴Cu-radiopharmaceuticals to be transported to distant medical units, which is convenient for dose preparation and clinical practice. This paper selectively reviewed the progresses in clinical research conducted on ⁶⁴Cu-radiopharmaceuticals in the past decade, hoping to provide some references and ideas for the future research and development of ⁶⁴Cu-radiopharmaceuticals. It is expected that ⁶⁴Cu-radiopharmaceuticals will be approved for the diagnosis of neuroendocrine tumors, prostate cancer and other diseases in the near future.

Key words: ⁶⁴Cu-radiopharmaceuticals, clinical trial, neuroendocrine tumors, hypoxia, prostate cancer

摘要：

正电子发射型计算机断层显像（positron emission computed tomography, PET）是核医学重要的诊断及显像工具，具有良好的灵敏度、分辨率和安全性，广泛应用于肿瘤、心脑血管等疾病的诊断。⁶⁴Cu核素因其适宜的半衰期（12.7 h）、独特的衰变性质（β⁺衰变、β^-衰变、电子俘获），以及可与多种配体配位形成配合物等特点，现已成为PET分子探针及诊疗一体化药物领域的研究热点。目前，有30多项针对⁶⁴Cu标记药物的临床研究正在开展，主要集中在神经内分泌肿瘤、肿瘤乏氧、前列腺癌等方面；结果表明，⁶⁴Cu标记药物的PET显像具有较高的分辨率、检出率，以及良好的安全性，另外⁶⁴Cu相对较长的半衰期使得⁶⁴Cu核素及其药物可运输至距离较远的医疗单位，方便药物制备及临床使用。本文对近十年来⁶⁴Cu标记药物在肿瘤诊断方面的临床研究进展进行了总结，以期为今后⁶⁴Cu标记药物的研发提供参考及思路；预期在不久的未来，将会有⁶⁴Cu标记药物获批应用于神经内分泌肿瘤、前列腺癌等疾病的诊断。

关键词: ⁶⁴Cu标记药物, 临床研究, 神经内分泌肿瘤, 乏氧, 前列腺癌

ZHAO Hailong;LI Hongyu. Research Progress of ⁶⁴Cu-Radiopharmaceuticals in Clinical Trial for Tumor Diagnosis[J]. Journal of Isotopes, 2021, 34(1): 78-88.

赵海龙;李洪玉. 肿瘤诊断⁶⁴Cu标记药物临床研究进展[J]. 同位素, 2021, 34(1): 78-88.

References

［1］Jackson I M, Scott P J H, Thompson S. Clinical applications of radiolabeled peptides for PET［J］. Seminars in Nuclear Medicine, 2017, 47(5): 493-523.
［2］Riola-Parada C, Garcia-Canamaque L, Perez-Duenas V, et al. Simultaneous PET/MRI vs PET/CT in oncology. A systematic review［J］. Revista Española de Medicina Nuclear e Imagen Molecular, 2016, 35(5): 306-312.
［3］Follacchio G A, De Feo M S, De Vincentis G, et al. Radiopharmaceuticals labelled with copper radionuclides: Clinical results in human beings［J］. Current Radiopharmaceuticals, 2018, 11(1): 22-33.
［4］Boschi A, Martini P, Janevik-Ivanovska E, et al. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics［J］. Drug Discovery Today, 2018, 23(8): 1489-1501.
［5］Evangelista L, Luigi M, Cascini G L. New issues for copper-64: From precursor to innovative PET tracers in clinical oncology［J］. Current Radiopharmaceuticals, 2013, 6(3): 117-123.
［6］Brandt M, Cardinale J, Aulsebrook M L, et al. An overview of PET radiochemistry, Part 2: radiometals［J］. The Journal of Nuclear Medicine, 2018, 59(10): 1500-1506.
［7］Jalilian A R, Jr J O. The current status and future of theranostic Copper-64 radiopharmaceuticals［J］. Iranian Journal of Nuclear Medicine, 2017, 25(1): 1-10.
［8］Mcmillan D D, Maeda J, Bell J J, et al. Validation of ⁶⁴Cu-ATSM damaging DNA via high-LET Auger electron emission［J］. Journal of Radiation Research, 2015, 56(5): 784-791.
［9］陈文，魏洪源，周志军，等. 金属正电子核素⁶⁴Cu,⁶⁸Ga,⁸⁶Y和⁸⁹Zr的PET标记药物研究进展［J］. 同位素,2017,30(1):78-88.Chen Wen, Wei Hongyuan, Zhou Zhijun, et al. Positron emission radiometals ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr labeled PET drugs［J］. Journal of Isotopes, 2017, 30(1): 78-88(in Chinese).
［10］孙夕林，闫龙天，王凯，等. 医用回旋加速器的⁶⁴Cu高效制备［J］. 现代生物医学进展,2016,16(19):3783-3787.Sun Xilin, Yan Yan, Wang Kai, et al. Medical cyclotron production of ⁶⁴Cu［J］. Progress in Modern Biomedicine, 2016, 16(19): 3783-3787(in Chinese).
［11］沈亦佳，陈玉清，梁积新，等. 电沉积法制备加速器生产⁶⁴Cu的镍靶［J］. 同位素,2013,26(1):38-41.Shen Yijia, Chen Yuqing, Liang Jixing, et al. Preparation of Ni target for cyclotron-produced ⁶⁴Cu by electrodeposition［J］. Journal of Isotopes, 2013, 26(1): 38-41(in Chinese).
［12］马磊，刘宇，柴之芳. ⁶⁴Cu放射性药物化学［J］. 化学进展,2012(9):1720-1728.Ma Lei, Liu Yu, Chai Zhifang. ⁶⁴Cu radiopharmaceutical chemistry［J］. Progress in chemistry, 2012(9): 1720-1728.
［13］Wadas T J, Wong E H, Weisman G R, et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease［J］. Chemical Reviews, 2010, 110(5): 2858-2902.
［14］Uri I, AvnielPolak S, Gross D J, et al. Update in the therapy of advanced neuroendocrine tumors［J］. Current Treatment Options in Oncology, 2017, 18(12): 72.
［15］崔璨，杨吉刚. 神经内分泌肿瘤的核医学影像诊断方法［J］. 临床和实验医学杂志,2014,13(22):1911-1915.Cui Can, Yang Jigang. Nuclear medicine imaging diagnosis method of neuroendocrine tumor［J］. Journal of Clinical and Experimental Medicine, 2014, 13(22): 1911-1915(in Chinese).
［16］Pfeifer A, Knigge U, Mortensen J, et al. Clinical PET of neuroendocrine tumors using ⁶⁴Cu-DOTATATE: First-in-humans study［J］. The Journal of Nuclear Medicine, 2012, 53(8): 1207-1215.
［17］Pfeifer A, Knigge U, Binderup T, et al. ⁶⁴Cu-DOTATATE PET for neuroendocrine tumors: A prospective Head-to-Head comparison with ¹¹¹In-DTPA-Octreotide in 112 patients［J］. The Journal of Nuclear Medicine, 2015, 56(6): 847-854.
［18］Johnbeck C B, Knigge U, Loft A, et al. Head-to-head comparison of 64Cu-DOTATATE and ⁶⁸Ga-DOTATOC PET/CT: A prospective study of 59 patients with neuroendocrine tumors［J］. The Journal of Nuclear Medicine, 2017, 58(3): 451-457.
［19］Carlsen E A, Johnbeck C B, Binderup T, et al. ⁶⁴Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms［J］. The Journal of Nuclear Medicine, 2020: 119.240143(ahead of print).
［20］Paterson B M, Roselt P, Denoyer D, et al. PET imaging of tumours with a ⁶⁴Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate［J］. Dalton Transactions, 2014, 43(3): 1386-1396.
［21］Hicks R J, Jackson P, Kong G, et al. ⁶⁴Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy［J］. The Journal of Nuclear Medicine, 2019, 60(6): 777-785.
［22］U.S. National Library of Medicine. ClinicalTrials.gov［DB/OL］. ［2020-05-28］. https:∥clinicaltrials.gov/ct2/results?cond=&term=SARTATE&cntry=&state=&city=&dist=［Z］.
［23］Clarity Pharmaceuticals. Clarity Pharmaceuticals Announces US FDA Grants ⁶⁷Cu-SARTATE? Orphan Drug Designation for Neuroblastoma ［EB/OL］. ［2020-05-28］. https:∥www.claritypharmaceuticals.com/news/odd_status/.
［24］Clarity Pharmaceuticals. Clarity Pharmaceuticals announces US FDA grants ⁶⁴Cu-SARTATE? Orphan Drug Designation for the clinical management of neuroblastoma［EB/OL］. ［2020-05-28］. https:∥www.claritypharmaceuticals.com/news/odd_status-diagnostic/.
［25］Kinzler K W, Vogelstein B. Life (and death) in a malignant tumour［J］. Nature, 1996, 379(6 560): 19-20.
［26］Lewis J S, Welch M J. PET imaging of hypoxia［J］. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2001, 45(2): 183-188.
［27］Lewis J S, Connett J M, Garbow J R, et al. Copper-64-pyruvaldehyde-bis (N4-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: Monitoring therapy response with microPET and magnetic resonance imaging［J］. Cancer Research, 2002, 62(2): 445-449.
［28］Grassi I, Nanni C, Cicoria G, et al. Usefulness of ⁶⁴Cu-ATSM in head and neck cancer: A preliminary prospective study［J］. Clinical Nuclear Medicine, 2014, 39(1): e59-e63.
［29］Lopci E, Grassi I, Rubello D, et al. Prognostic evaluation of disease outcome in solid tumors investigated with 64Cu-ATSM PET/CT［J］. Clinical Nuclear Medicine, 2016, 41(2): e87-e92.
［30］U.S. National Library of Medicine. ClinicalTrials.gov［DB/OL］. ［2020-05-28］. https:∥clinicaltrials.gov/ct2/show/NCT03951337?term=ATSM&draw=2&rank=1［Z］.
［31］U.S. National Library of Medicine. ClinicalTrials.gov［DB/OL］. ［2020-05-28］. https:∥clinicaltrials.gov/ct2/show/NCT00794339?term=ATSM&draw=2&rank=4［Z］.
［32］Ghosh A, Heston W D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer［J］. Journal of Cellular Biochemistry, 2004, 91(3): 528-539.
［33］Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues［J］. World Journal of Surgery, 2006, 30(4): 628-636.
［34］Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy［J］. The Journal of Nuclear Medicine, 2015, 56(5): 668-674.
［35］Grubmüller B, Baum R P, Capasso E, et al. ⁶⁴Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies［J］. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31(8): 277-286.
［36］Cantiello F, Gangemi V, Cascini G L, et al. Diagnostic accuracy of (64)Copper prostate-specific membrane antigen positron emission Tomography/Computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: Our preliminary experience［J］. Urology, 2017, 106: 139-145.
［37］Avila-Rodriguez M A, Rios C, Carrasco-Hernandez J, et al. Biodistribution and radiation dosimetry of ［⁶⁴Cu］copper dichloride: First-in-human study in healthy volunteers［J］. EJNMMI Research, 2017, 7: 98.
［38］Piccardo A, Paparo F, Puntoni M, et al. ⁶⁴CuCl₂ PET/CT in prostate cancer relapse［J］. The Journal of Nuclear Medicine, 2018, 59(3): 444-451.
［39］Righi S, Ugolini M, Bottoni G, et al. Biokinetic and dosimetric aspects of ⁶⁴CuCl₂in human prostate cancer: Possible theranostic implications［J］. EJNMMI Research, 2018, 8: 18.
［40］Shariat S F, Roehrborn C G, Mcconnell J D, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis［J］. Journal of Clinical Oncology, 2007, 25(4): 349-355.
［41］Ganesh S, Sier C M, Heerding M, et al. Urokinase receptor and colorectal cancer survival［J］. The Lancet, 1994, 344(8919): 401-402.
［42］Persson M, Skovgaard D, Brandt-Larsen M, et al. First-in-human uPAR PET: Imaging of cancer aggressiveness［J］. Theranostics, 2015, 5(12): 1303-1316.
［43］U.S. National Library of Medicine. ClinicalTrials.gov［DB/OL］. ［2020-05-28］. https:∥clinicaltrials.gov/ct2/show/NCT02139371?term=⁶⁴Cu-DOTA-AE105&draw=2&rank=1［Z］.
［44］Tamura K, Kurihara H, Yonemori K, et al. ⁶⁴Cu-DOTA-trastuzumab PET imaging in patients with HER2-Positive breast cancer［J］. The Journal of Nuclear Medicine, 2013, 54(11): 1869-1875.
［45］Joanne E M, James R B, David M C, et al. Functional imaging of human epidermal. growth factor receptor 2-positive metastatic breast cancer using ⁶⁴Cu-DOTA-trastuzumab PET［J］. The Journal of Nuclear Medicine, 2014, 55(1): 23-29.
［46］Mortimer J E, Bading J R, Park J M, et al. Tumor uptake of ⁶⁴Cu-DOTA-trastuzumab in patients with metastatic breast cancer［J］. The Journal of Nuclear Medicine, 2018, 59(1): 38-43.
［47］U.S. National Library of Medicine. ClinicalTrials.gov［DB/OL］. ［2020-05-28］. https:∥clinicaltrials.gov/ct2/show/NCT02827877?term=⁶⁴Cu-DOTA-trastuzumab&draw=2&rank=3［Z］.

[1]	LIU Jingru;ZHU Hong. Research Progress of Radionuclide-Labeled PSMA Ligands in the Diagnosis and Treatment of Prostate Cancer [J]. Journal of Isotopes, 2020, 33(4): 241-249.
[2]	ZHU Hua;LIU Teli;WANG Feng;JIANG Jinquan;HAN Xuedi;YANG Zhi. Preparation, Quality Control and Biodistribution Analysis of ⁶⁴Cu Labeled DKFZ-PSMA-617 and its Clinical Translation Research [J]. Journal of Isotopes, 2019, 32(6): 382-387.
[3]	ZHANG Xiaojun;FU Huaping;LI Yungang;LIU Jian;HE Yulin;LIU Yachao;XU Baixuan;ZHU Hong;WU Jiang;CUI Mengchao;ZHANG Jinming. Preparation and Clinical Application of ¹⁸F-DCFPyL [J]. Journal of Isotopes, 2018, 31(5): 291-297.
[4]	zhi yang. Preparation and Preliminary Evaluation of the in vivo and in vitro hypoxic selectivity of a novel hypoxic agent 99Tcm-N4IPA [J]. Journal of Isotopes, 2008, 21(2): 95-101.
[5]	. New Advances of Somatostatin Receptor-targeted Radionuclide Therapy for Neuroendocrine Tumors [J]. Journal of Isotopes, 2005, 18(3 ): 173-173 .
[6]	. The Development ~(18)F Labeled Hypoxic Imaging Agents [J]. Journal of Isotopes, 2004, 17 (4 ): 241-241 .
[7]	. Preparation of the Hypoxia-imaging Agent ~(99)Tc~m-N4AIPO Kit [J]. Journal of Isotopes, 2004, 17 (1 ): 11-11 .
[8]	. Preparation of the Hypoxia-imaging Agent ~(99)Tc~m-N4AIPO Kit [J]. Journal of Isotopes, 2004, 17 (1 ): 11-11 .
[9]	. Study on HL91 Single-kit Formulation Labelling With ~(99)Tc~m for Hypoxia Tissue Imaging [J]. Journal of Isotopes, 2003, 16(Z1 ): 171-171 .
[10]	. The Dynamic of Cardiac Myocyte Hypoxia Trapping ~(99)Tc~m-HL91 [J]. Journal of Isotopes, 2002, 15 (3 ): 151-151 .

Research Progress of ⁶⁴Cu-Radiopharmaceuticals in Clinical Trial for Tumor Diagnosis

肿瘤诊断⁶⁴Cu标记药物临床研究进展

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics